Publications

A real-world study to evaluate the safety and efficacy of three injectable neurokinin-1 receptor antagonist formulations for the prevention of chemotherapy-induced nausea and vomiting in cancer patients

The Safety and Efficacy of Fostamatinib in Patients with Chronic Immune Thrombocytopenic Purpura Treated in a Real-World Community Hematology Setting

A Real-World Comparative Effectiveness Analysis of Fostamatinib vs Thrombopoietic Receptor Agonists for the Treatment of Chronic Immune Thrombocytopenia in Adult Patients

Development of a Diagnostic Algorithm for the Early Identification of Patients with Systemic Mastocytosis

Development and Validation of a Diagnostic Tool for the Timely Diagnosis of Patients with Systemic Mastocytosis

Diagnosis and management of systemic mastocytosis in a community hematology setting

A Real-World Comparative Analysis of Hypertension and Time to Treatment Failure with Acalabrutinib Vs Ibrutinib in Treatment-Naïve Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

A Real-World Exploratory Analysis to Identify Disparities in Breast Cancer Tumor Biopsy Practice at Community Oncology Clinics in the United States

Real-World Study Evaluating Drug Tolerability and Health Care Resource Use (HCRU) With Acalabrutinib vs. Ibrutinib in Treatment-Naïve Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Real-World Study Evaluating Drug Tolerability and Health Care Resource Use (HCRU) With Acalabrutinib vs Ibrutinib in Patients With Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

A REAL-WORLD COMPARISON OF HYPERTENSION AND CARDIOVASCULAR ADVERSE EVENTS WITH ACALABRUTINIB VS IBRUTINIB IN PATIENTS WITH TREATMENT-NAIVE CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA

A real-world comparative study of hypertension (HTN) and time to treatment failure (TTF) with acalabrutinib versus ibrutinib in treatment-naive Medicare-eligible patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

A real-world comparative analysis of cardiovascular (CV) safety and time to next treatment (TTNT) with acalabrutinib versus ibrutinib in treatment-naive patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

Effective biomarker testing rates in advanced non-small cell lung cancer (NSCLC) patients in U.S. community oncology practices

Disparities in Biopsy Practice in Metastatic Breast Cancer Patients Managed in Community Oncology Practices in the United States: Implications for Guideline-Concordant Care

A real-world study evaluating drug tolerability and health care resource use with acalabrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma

Real-world Clinical Outcomes in Patients with HER2+ Metastatic Breast Cancer Treated with Trastuzumab Deruxtecan After One or More Prior Lines of Therapy: Data from U.S. Community Oncology Practices

Real-world Clinical Outcomes of Trastuzumab Deruxtecan Among HER2+ Metastatic Breast Cancer Patients with and without Brain Metastases: Data from U.S. Community Oncology Practices

Real-World Experience of Patients with Indolent Systemic Mastocytosis Treated with Avapritinib in a Community Oncology Setting

Racial Disparities in Biomarker Testing, Treatment Utilization, and Outcomes in Patients with Metastatic Triple-Negative Breast Cancer (mTNBC) in U.S. Community Practices

Trastuzumab Deruxtecan in HER2-Low Metastatic Breast Cancer: Real-World Treatment Patterns and Outcomes From Community Oncology Settings

Real-World Safety of Trastuzumab Deruxtecan in HER2-Low Metastatic Breast Cancer: Insights From US Community Oncology Practices

A Framework for Incorporating Distance-to-Care Metrics in Cancer Outcomes Research: Exploratory Insights using Real-world Data from a Network of Community Practices

Real-World Del(17p), TP53, and IGHV Baseline Testing Patterns in Chronic Lymphocytic Leukemia (CLL) Within a Large Network of US Community Oncology Practices

Evaluating Effective Biomarker Testing for Advanced Non–Small Cell Lung Cancer in US Community Oncology Practices

Hypertension and Time to Treatment Failure with Acalabrutinib and Ibrutinib in Treatment-Naïve CLL/SLL